1. Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP
- Author
-
Ari M. P. Koskinen, Gretchen A. Repasky, Laura Turunen, Arjan J. van Adrichem, Anna Lehto, Krister Wennerberg, Annika E Fagerholm, Jani Saarela, Department of Chemistry, Aalto-yliopisto, and Aalto University
- Subjects
GTPase-activating protein ,RAC1 ,cytokinesis ,CDC42 ,GTPase ,Biology ,Biochemical assays ,Article ,Cell Line ,Small Molecule Libraries ,03 medical and health sciences ,0302 clinical medicine ,Cell Movement ,Drug Discovery ,Animals ,Humans ,Enzyme Inhibitors ,ta116 ,030304 developmental biology ,MgcRacGAP ,0303 health sciences ,Organic Chemistry ,Cell Cycle ,GTPase-Activating Proteins ,small molecule inhibitor ,biochemical assays ,General Medicine ,Small molecule ,3. Good health ,Computer Science Applications ,Cell biology ,High-Throughput Screening Assays ,HTS ,Ras superfamily ,030217 neurology & neurosurgery ,Cytokinesis ,Rac1 ,HeLa Cells - Abstract
The Rho family of Ras superfamily small GTPases regulates a broad range of biological processes such as migration, differentiation, cell growth and cell survival. Therefore, the availability of small molecule modulators as tool compounds could greatly enhance research on these proteins and their biological function. To this end, we designed a biochemical, high throughput screening assay with complementary follow-up assays to identify small molecule compounds inhibiting MgcRacGAP, a Rho family GTPase activating protein involved in cytokinesis and transcriptionally upregulated in many cancers. We first performed an in-house screen of 20,480 compounds, and later we tested the assay against 342,046 compounds from the NIH Molecular Libraries Small Molecule Repository. Primary screening hit rates were about 1% with the majority of those affecting the primary readout, an enzyme-coupled GDP detection assay. After orthogonal and counter screens, we identified two hits with high selectivity towards MgcRacGAP, compared with other RhoGAPs, and potencies in the low micromolar range. The most promising hit, termed MINC1, was then examined with cell-based testing where it was observed to induce an increased rate of cytokinetic failure and multinucleation in addition to other cell division defects, suggesting that it may act as an MgcRacGAP inhibitor also in cells.
- Published
- 2015